Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing of extra care may boost quality of life in myeloma patients

NCT ID NCT05355987

Symptom relief Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether starting supportive care (like meetings with a nurse, psychologist, or dietitian) right after a multiple myeloma diagnosis helps patients feel better compared to waiting 6 months. Twenty patients took part, and researchers measured their quality of life using a special questionnaire. The goal is to find the best time to offer these extra services to improve well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
early paramedical supportive care consultations (nurse, social worker, psychologist, physiotherapist, etc.)
What this could lead to
If it works, this could show that starting supportive care right at diagnosis helps multiple myeloma patients feel better and have a higher quality of life.
What could go wrong
This is a very small, completed study with only 20 participants, so results may not apply to everyone. It tests timing of support, not a new drug, so the impact is modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Jun 2022

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age superior to 18 years old * Patient recently diagnosed with multiple myeloma not eligible to autologous blood stem-cell transplantation, before starting therapy in day hospital * Patient coming regularly to Centre Henri Becquerel for treatment and follow up for multiple myeloma * Informed consent form signed Exclusion Criteria: * Inclusion Criteria: * Age superior to 18 years old * Patient recently diagnosed with multiple myeloma not eligible to autologous blood stem-cell transplantation, before starting therapy in day hospital * Patient coming regularly to Centre Henri Becquerel for treatment and follow up for multiple myeloma * Informed consent form signed Exclusion Criteria: * Patient with urgent need of treatment after multiple myeloma diagnosis with urgent and absolute need of oncological supportive care immediately after diagnosis * Patient deprived of liberty, under judicial supervision, under guardianship or trusteeship * History of psychological or sensorial disorder or anomaly that can prevent the patient from understanding the conditions for study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Centre Henri Becquerel

    Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.